Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Can We Apply Leadership Skills to Writing Pharmacovigilance SOPs?
Posted on August 18th, 2017 by J.-P. Clement MD
Pharmacovigilance
The Policies, Procedures and other Quality Documents that we use as a backbone to our daily PV activities are the fundamental references for ensuring the consistency of the execution of our activities. They also ensure adequate documentation Continue reading “Can We Apply Leadership Skills to Writing Pharmacovigilance SOPs?” »
Overcoming Commercial, Technical & Regulatory Challenges in Drug Discovery
Posted on August 16th, 2017 by Christine de Vries - Scheidegger
Chemistry
R&D departments find themselves having to work with budgets that seem to get tighter all the time. One of the best ways of ensuring that investments are used on projects with the greatest probability of success Continue reading “Overcoming Commercial, Technical & Regulatory Challenges in Drug Discovery” »
Using Machine Learning for Identifying and Classifying Patient Groups
Posted on August 14th, 2017 by Dr Andrew A. Parsons
Pharma R&D
To maximize value to payers, patients, and practitioners, pharma R&D wants to ensure that new medicines are given to the right patient, at the right time and at the right dose. To do this appropriately, we need ways to classify or diagnose patient groups.
Continue reading “Using Machine Learning for Identifying and Classifying Patient Groups” »
Delivering the Right Therapy to the Right Patient with ADCs
Posted on August 11th, 2017 by Patricia Morgan
Pharma R&D
One of the most powerful tools in the fight against cancer has become the patient’s very own immune system. Among the many approaches that researchers are exploring is the use of antibody-drug conjugates (ADCs) Continue reading “Delivering the Right Therapy to the Right Patient with ADCs” »
Assessing DDI Risk in the Digital Age
Posted on August 9th, 2017 by Sherry Winter
Pharmacovigilance
In their 2012 Drug Regulations, the U.S. Food and Drug Administration recommended that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development.”
The Eternal Triangle of Quality, Speed, and Cost
Posted on August 7th, 2017 by Dr Andrew A. Parsons
Pharma R&D
A designer colleague once described to me the key issue involved in many of their creative design projects. It is finding the best balance between quality, speed, and cost. From a buyer perspective, we desire high quality, rapid delivery, and low cost. Continue reading “The Eternal Triangle of Quality, Speed, and Cost” »
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, Â its affiliates and sponsors or its parent company, Reed Elsevier.
